Partner With Us NRI

Caplin Point Laboratories Ltd share Price

Company details

6M Return -17.37%
1Y Return -17.21%
Mkt Cap.(Cr) 4,504.95
Volume 12,717
Div Yield 0.68%
OI Chg %
Volume 12,717

Open Free Trading Account Online with ICICIDIRECT

US momentum drives growth; LatAm steady…

About The Stock

    Caplin derives entire revenues through exports with 90% of revenues from Emerging Markets (LatAm + RoW) where it has an end-to-end business model through last mile logistical solutions for its exclusive distributors.

    • In the US, Caplin has filed 21 ANDAs on its own and through partners, 18 approvals from the USFDA (five with partners)
    • For LatAm markets, it outsources ~40% of products from China, ~20% from Indian vendors and in-house manufacturing of the remaining ~40%
    • Caplin Steriles caters to the rapidly growing demand for injectable products in US and other regulated markets


    Growth driven by core geographies and better offtake in US

    • Sales were up 22% YoY to ₹ 339 crore
    • EBITDA was at ₹ 100 crore, up 17% YoY with margins at 29.5%
    • Consequent PAT was at ₹ 79 crore (up 19% YoY)

Click here for full recommendation

Research view on more stocks

Caplin Point Laboratories Ltd.

Q3FY23 Quarterly Result Announced for Caplin Point Laboratories Ltd.

Caplin Point Laboratories announced Q3FY23 results:

  • Consolidated Q3FY23 & 9MFY23:
    • Q3FY23 revenue at Rs 386 crore, up 15.0% YoY, as compared to Rs 336 crore in Q3FY22
    • PAT for the quarter is at Rs 97 crore, up 22.8% as compared to Rs 79 crore in Q3FY22
    • PAT increased by 21.1% to Rs 276 crore in 9MFY23, against Rs 228 crore in 9MFY22
    • Cash flow from operations at Rs 176 crore for 9MFY23 
    • Basic EPS grew by 24% to Rs 36.17 in 9MFY23 against Rs 29.18 in 9MFY22 (not annualized)
    • With the depreciation of INR against USD, exchange gain in 9MFY23 is Rs 13.16 crore vs Rs 8.24 crore in 9MFY22
    • Enhanced deployment of cash has yielded an interest income of Rs 26 crore in 9MFY23 vs Rs.16 crore in 9MFY22
    • Considering the extended transit time and with a focus on the need to keep Inventory closer to customers, the current level of inventory is likely to continue in Q4 as well
    • Geographical breakup of sales: LATAM & ROW: 86%, US: 14%
  • Consolidated 9MFY23:
    • Revenue for 9MFY23 grew by 17.2% YoY to Rs 1,122 crore
    • Gross margins for 9MFY23 are at 54.8%
    • EBITDA for 9MFY23 is Rs 362 crore; EBITDA margin at 32.2%
    • 9MFY23 PAT is at Rs 276 crore, up 21.1% YoY
    • Cash and cash equivalents at Rs 718 crore. Capex for 9MFY23 is at Rs 154 crore. Free cash flow for the period was Rs 22 crore
    • Receivable stood stable around 100 days as of 9MFY23

Result PDF

View Other Company Results


Investment recommendation

US momentum drives growth; LatAm steady…

Call Date

14 Feb 2023

Entry Price


Target Price



12-18 Month



Operating Profit

Profit after Tax


Reserves and Surplus



Operating Profit

Profit after Tax




Caplin Point Laboratories Ltd Stocks COMPARISION


Equity Capital: 1,483.93 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 22,948.47 4,147.77
LAST 3M 50,808.43 -11,347.14
LAST 6M 78,521.89 15,105.83
LAST 12M 169,956.63 -37,974.87

Caplin Point Laboratories Limited - Loss of Share Certificates

Mar 27, 2023 l NSE Announcement

Caplin Point Laboratories Limited - Loss of Share Certificates

Mar 24, 2023 l NSE Announcement

Caplin Point Laboratories Limited - Loss of Share Certificates

Mar 23, 2023 l NSE Announcement

Date Action Type Ratio
Sep 21, 2022 Dividend 100
May 23, 2022 Dividend 100
Sep 20, 2021 Dividend 75

Caplin Point Laboratories Ltd Information

Stock PE (TTM)


Promoter Holding


Book Value







  • Caplin Point Laboratories Ltd. is a fast-growing, fully integrated pharmaceutical company thriving in Francophone Africa and Latin America. It manufactures a wide range of creams, ointments, and other external application preparations, along with regular segments of pharmaceutical formulations. The company was incorporated in 1990, with its headquarters in Chennai. Its total income for the June 2022 quarter was Rs 360.27 crore, up 2.71% from Rs 350.75 crore in the March 2022 quarter. On 30 August 2022, the company’s market capitalisation stood at Rs 5,903 crore.  

    The company’s Bombay Stock Exchange listing code is 524742, and the National Stock Exchange listing code is CAPLIPOINT.  

    Caplin Point Laboratories Ltd. is one of the leading suppliers of pharmaceuticals in the markets of Latin America, Southern and Francophone Africa, and the Caribbean, with more than 4,000 product licenses worldwide. The company prospers on a unique business model of owning distribution networks, predominantly targeting the bottom of the pyramid.  

    On 30 June 2022, the company’s shareholding pattern reflected a 1.11% domestic institutional investor stake, a 2.03% foreign institutional investor stake, a 27.97% public stake, and a 68.88% promoter stake. In the June 2022 quarter, promoter holdings decreased from 68.89% to 68.88%, mutual fund holdings decreased from 1.19% to 1.06%, and FII holdings decreased from 2.07% to 2.03%.  

    The company’s board of directors comprises Mr C CPaarthipan, Dr Sridhar Ganesan, Mr D Sathyanarayanan, Mr V Thirumalai, Dr KC John, Dr (Mrs) C K Gariyali, and Mr R Viswanathan. The auditors of the company are CNGSN & Associates LLP. On 30 June 2022, the company had a total of 7.58 crore shares outstanding.  

    On 30 August 2022, Caplin Point Laboratories Ltd.’s share price closed at Rs 776.90 on BSE and at Rs 778.80 on NSE. The 52-week high for Caplin Point Laboratories Ltd.’s share price was Rs 1,008.40, and the 52-week low for the company’s share price was Rs 626.  

    As of July 2022, the company’s top mutual fund holdings included Taurus Discovery (Midcap) Fund, Taurus Ethical Fund, and Quant Small Cap Fund, with a 3.36% stake, 3.08% stake, and 2.43% stake, respectively.  

    Caplin Point Laboratories Ltd.’s peers include Sun Pharmaceutical Industries Ltd., Divis Laboratories Ltd., Cipla Ltd., and Dr Reddys Laboratories Ltd. 

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest.  I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose 

Registered Address

Ashvich Towers 3rd Floor, No 3 Developed Plots Ind Estat, Chennai, Tamil Nadu, 600096

Tel : 91-44-24968000/71148000/28156653
Email : investor:caplinpoint.net/info:caplinepoint.net
Website : http://www.caplinpoint.net


Knack Corporate Services Pvt L

AGM Date (Month) : Sep
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 524742
Book Closure Date (Month) :
BSE Group : A
ISIN : INE475E01026

FAQ’s on Caplin Point Laboratories Ltd Shares

You can buy Caplin Point Laboratories Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Caplin Point Laboratories Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Mar 27, 2023 04:01 PM the closing price of Caplin Point Laboratories Ltd was ₹ 593.60.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Mar 27, 2023 04:01 PM, the market cap of Caplin Point Laboratories Ltd stood at ₹ 4,504.95.

The latest PE ratio of Caplin Point Laboratories Ltd as of Mar 27, 2023 04:01 PM is 12.7

The latest PB ratio of Caplin Point Laboratories Ltd as of Mar 27, 2023 04:01 PM is 0.38

The 52-week high of Caplin Point Laboratories Ltd is ₹ 856.00 while the 52-week low is ₹ 588.40

According to analyst recommendations, Caplin Point Laboratories Ltd has a “Buy” rating for the long term.

Download Our App

market app
market app